Bertrand Leo Chenard
Corporate Officer/Principal bij Hydra Biosciences, Inc.
Profiel
Bertrand Leo Chenard is the founder of Cadent Therapeutics, Inc. (founded in 2010).
He is currently the Senior President-Chemistry & Pharmacology at Hydra Biosciences, Inc. Bertrand's former positions include being a Research Scientist-Central Research Department at EIDP, Inc., Senior Vice President-Chemistry & Process Research at Neurogen Corp., and a Project Coordinator & Research Advisor at Pfizer Inc. Bertrand's education includes an undergraduate degree from Central Connecticut State University and a doctorate from The Ohio State University.
Actieve functies van Bertrand Leo Chenard
| Bedrijven | Functie | Begin |
|---|---|---|
Hydra Biosciences, Inc.
 Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | Corporate Officer/Principal | - |
Eerdere bekende functies van Bertrand Leo Chenard
| Bedrijven | Functie | Einde |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Oprichter | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
| E I DU PONT DE NEMOURS AND CO | Corporate Officer/Principal | - |
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Corporate Officer/Principal | - |
Opleiding van Bertrand Leo Chenard
| Central Connecticut State University | Undergraduate Degree |
| The Ohio State University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Neurogen Corp.
Neurogen Corp. Pharmaceuticals: MajorHealth Technology Neurogen Corp. operated as a drug discovery and development company. The company was headquartered in Branford, CT. | Health Technology |
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
Hydra Biosciences, Inc.
Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
